2010
Comparison of Catheterization Laboratory Initiated Abciximab and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes (an ACUITY Substudy)
Kirtane AJ, Parise H, Mehran R, Moses JW, Fahy M, Bertrand ME, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Ware JH, Pocock SJ, Lansky AJ, Stone GW. Comparison of Catheterization Laboratory Initiated Abciximab and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes (an ACUITY Substudy). The American Journal Of Cardiology 2010, 106: 180-186. PMID: 20599000, DOI: 10.1016/j.amjcard.2010.03.015.Peer-Reviewed Original ResearchConceptsAcute coronary syndromePercutaneous coronary interventionCoronary syndromeCoronary interventionTreatment selectionHigh-risk acute coronary syndromesUrgent Intervention Triage Strategy (ACUITY) trialGlycoprotein IIb/IIIa inhibitorsBaseline cardiac risk factorsNet clinical adverse eventsIIb/IIIa inhibitorsPrevious revascularization proceduresUse of abciximabCardiac risk factorsStudy end pointClinical adverse eventsImproved clinical outcomesST-segment deviationAcute CatheterizationComposite ischemiaMajor bleedingIschemic complicationsAdverse eventsBiomarker elevationRevascularization procedures
2004
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale
Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, Lansky AJ, Lincoff AM, Mehran R, Moses JW, Ohman M, White HD. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale. American Heart Journal 2004, 148: 764-775. PMID: 15523305, DOI: 10.1016/j.ahj.2004.04.036.Peer-Reviewed Original ResearchMeSH KeywordsAngina, UnstableAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsCardiac CatheterizationCombined Modality TherapyCoronary Artery BypassEnoxaparinHeparinHirudinsHumansMulticenter Studies as TopicMyocardial InfarctionPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRandomized Controlled Trials as TopicRecombinant ProteinsResearch DesignConceptsIIb/IIIa inhibitionUrgent Intervention Triage Strategy (ACUITY) trialIIb/IIIa inhibitorsAcute CatheterizationInhibitor administrationStrategy trialMyocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary study end pointAdverse ischemic eventsHigh-risk ACSComposite of deathStudy end pointAcute coronary syndromeHigh-risk patientsSurgical revascularization proceduresTreatment of choiceSecond random assignmentACUITY trialMajor bleedingSurgical revascularizationUnplanned revascularizationCoronary syndromeEarly angiographyIschemic events
1999
Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion
Teirstein P, Mann J, Cundey P, Schechter E, Jacobs W, Grines C, Stagaman D, Lansky A, Hultquist M, Kusnick B, Heuser R, Kleinert H, Popma J. Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion. The American Journal Of Cardiology 1999, 83: 1623-1628. PMID: 10392865, DOI: 10.1016/s0002-9149(99)00163-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticoagulantsCerebral HemorrhageChronic DiseaseCoronary AngiographyCoronary DiseaseDose-Response Relationship, DrugFemaleGraft Occlusion, VascularHeparinHumansInfusions, IntravenousMaleMiddle AgedPlasminogen ActivatorsRecombinant ProteinsSaphenous VeinUrokinase-Type Plasminogen ActivatorConceptsSaphenous vein graftsR-UKStudy drugVein graftsMyocardial infarctionNon-Q-wave myocardial infarctionPrimary study end pointSaphenous vein graft occlusionHigh-dose armStudy end pointLife-threatening bleedingVein graft occlusionHigh-dose groupDuration of infusionRecombinant urokinaseAcceptable success rateIntracerebral bleedPercutaneous revascularizationFinal angiogramGraft occlusionRecanalization rateAngiographic analysisHuman kidney cellsAllergic reactionsLow dose